These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 9643375)

  • 1. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
    Meyer D; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques.
    Torres JV; Anderson DE; Malley A; Banapour B; Axthelm MK; Benjamini E; Gardner MB
    J Med Primatol; 1993; 22(2-3):129-37. PubMed ID: 7692056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation.
    Torres JV; Malley A; Banapour B; Anderson DE; Axthelm MK; Gardner MB; Benjamini E
    AIDS Res Hum Retroviruses; 1993 May; 9(5):423-30. PubMed ID: 7686386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells.
    Planelles V; Haigwood NL; Marthas ML; Mann KA; Scandella C; Lidster WD; Shuster JR; Van Kuyk R; Marx PA; Gardner MB
    AIDS Res Hum Retroviruses; 1991 Nov; 7(11):889-98. PubMed ID: 1760229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.
    Jurkiewicz E; Hunsmann G; Schäffner J; Nisslein T; Lüke W; Petry H
    J Virol; 1997 Dec; 71(12):9475-81. PubMed ID: 9371609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bovine alpha-2-HS-glycoprotein functions as a booster antigen for efficiently stimulating humoral immune responses to CCR5 and SIVmac239 envelope glycoprotein.
    Otsubo Y; Yashiro S; Nozaki K; Matsuura K; Kiyonaga K; Mitsumata R; Takahashi Y; Masuyama M; Muneoka A; Takamune N; Shoji S; Misumi S
    Biochem Biophys Res Commun; 2014 Jan; 443(1):301-7. PubMed ID: 24309114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.
    Buge SL; Richardson E; Alipanah S; Markham P; Cheng S; Kalyan N; Miller CJ; Lubeck M; Udem S; Eldridge J; Robert-Guroff M
    J Virol; 1997 Nov; 71(11):8531-41. PubMed ID: 9343211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
    Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypervariable epitope constructs as a means of accounting for epitope variability.
    Anderson DE; Malley A; Benjamini E; Gardner MB; Torres JV
    Vaccine; 1994 Jun; 12(8):736-40. PubMed ID: 7522382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.
    Mitchell WM; Torres J; Johnson PR; Hirsch V; Yilma T; Gardner MB; Robinson WE
    AIDS; 1995 Jan; 9(1):27-34. PubMed ID: 7893438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge.
    Mortara L; Letourneur F; Villefroy P; Beyer C; Gras-Masse H; Guillet JG; Bourgault-Villada I
    Virology; 2000 Dec; 278(2):551-61. PubMed ID: 11118377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination.
    McBride BW; Corthals G; Rud E; Kent K; Webster S; Cook N; Cranage MP
    J Gen Virol; 1993 Jun; 74 ( Pt 6)():1033-41. PubMed ID: 7685372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.